News - Kyowa Hakko Kirin, Licensing


Popular Filters

ProStrakan initiates EU launch of Sancuso


ProStrakan has started the European Union roll-out of its transdermal patch Sancuso for the prevention…

BiotechnologyEuropeKyowa Hakko KirinLicensingOncologyProStrakanSancuso

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23


Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Drug discovery alliances for Boehringer and Horizon Discovery; and NovAliX with Kyowa Hakko


UK-based Horizon Discovery, a provider of research tools to support the development of personalized medicines,…

Boehringer IngelheimHorizon DiscoveryKyowa Hakko KirinLicensingNovAliXOncologyPharmaceuticalResearch

Kyowa Hakko Kirin returns rights to Busulfex to Otsuka


Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has reached agreement on returning development and marketing…

BusulfexKyowa Hakko KirinLicensingOncologyOtsukaPharmaceutical

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko


Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Orexo and ProStrakan reconfigure rights to Abstral


Sweden's Orexo AB (STO: ORX) and Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa…

AbstralGlobalKyowa Hakko KirinLicensingOncologyOrexo ABPharmaceuticalProStrakan

Back to top